United States Biotechnology & Medical Research

Cyclerion Therapeutics Inc (CYCN)

Track

The most recent insider trading activity for Cyclerion Therapeutics Inc. occurred on November 21, 2024, when Slate Path Capital LP executed a sale of 357,880 shares valued at approximately $555,108. As this transaction took place more than three months ago, there has been no significant insider trading activity reported in the recent period.
Ticker: CYCN Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Cyclerion Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 21 Nov 2024
Value US$2,354,993.21 | Price 344.73 | Shares 22,322 (+18.5%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-11-25 2024-11-21 S Sale
0.5
Slate Path Capital LP
Large shareholder
22,322 +18.5%
344.73
US$2,354,993 		22,322 +18.5% 344.73 US$2,354,993
2023-08-11 2023-08-09 S Sale
1.4
MCGUIRE TERRANCE
Non-Executive Director
20,795 +19.7%
381.29
US$1,790,978 		20,795 +19.7% 381.29 US$1,790,978
2021-06-07 2021-06-03 B Purchase
2.6
Hecht Peter M

Chief Executive Officer

Executive Director
33,750 -10.0%
283.33
US$3,559,349 		33,750 -10.0% 283.33 US$3,559,349
2021-06-07 2021-06-03 B Purchase
1.4
MCGUIRE TERRANCE
Non-Executive Director
3,322 +15.4%
3.12
US$10,365 		3,322 +15.4% 3.12 US$10,365
2021-06-07 2021-06-03 B Purchase
1.4
MCGUIRE TERRANCE
Non-Executive Director
92,831 +15.4%
3.12
US$289,633 		92,831 +15.4% 3.12 US$289,633
2021-05-10 2021-05-06 B Purchase
2.6
Hecht Peter M

Chief Executive Officer

Executive Director
302,000 +32.7%
2.43
US$733,860 		302,000 +32.7% 2.43 US$733,860
2021-03-01 2021-02-25 PlS Planned sale
Gjino Anjeza

Chief Financial Officer

Officer
1,824 -5.5%
4.00
US$7,296 		1,824 -5.5% 4.00 US$7,296
2021-03-01 2021-02-25 PlS Planned sale
Wright Christopher I

Chief Medical Officer

Officer
2,637 -5.8%
3.99
US$10,522 		2,637 -5.8% 3.99 US$10,522
2020-12-30 2020-12-28 S Sale
2.0
Currie Mark G

President and CSO

Officer
20,107 -7.4%
3.01
US$60,522 		20,107 -7.4% 3.01 US$60,522
2020-11-12 2020-11-09 PP Planned purchase
4.2
Busch Andreas

Chief Innovation Officer

Officer
125,000 +96.4%
2.53
US$316,250 		125,000 +96.4% 2.53 US$316,250
2020-11-10 2020-11-06 PlS Planned sale
0.5
Huyett William

Chief Financial Officer

Officer
3,827 -5.4%
2.52
US$9,644 		3,827 -5.4% 2.52 US$9,644
2020-02-25 2020-02-21 PlS Planned sale
0.5
Huyett William

Chief Financial Officer

Officer
3,559 -4.7%
5.12
US$18,222 		3,559 -4.7% 5.12 US$18,222
2019-12-31 2019-12-30 S Sale
2.0
Currie Mark G

President

Officer
25,000 -8.4%
2.48
US$62,000 		25,000 -8.4% 2.48 US$62,000
2019-12-31 2019-12-27 S Sale Currie Mark G

President

Officer
25,000 -7.8%
2.55
US$63,750 		25,000 -7.8% 2.55 US$63,750
2019-11-19 2019-11-15 B Purchase Busch Andreas

Chief Innovation Officer

Officer
125,000 +inf%
1.82
US$227,500 		125,000 +inf% 1.82 US$227,500
2019-11-12 2019-11-08 PlS Planned sale Huyett William

Chief Financial Officer

Officer
3,922 -5.0%
2.05
US$8,040 		3,922 -5.0% 2.05 US$8,040
2019-04-10 2019-04-08 B Purchase
1.4
MCGUIRE TERRANCE
21,635 +inf%
16.00
US$346,160 		21,635 +inf% 16.00 US$346,160
2019-04-10 2019-04-08 B Purchase
1.4
MCGUIRE TERRANCE
604,482 +inf%
16.00
US$9,671,712 		604,482 +inf% 16.00 US$9,671,712
2019-04-10 2019-04-08 B Purchase
2.7
SCHULMAN AMY W
21,635 +inf%
16.00
US$346,160 		21,635 +inf% 16.00 US$346,160
2019-04-10 2019-04-08 B Purchase
2.7
SCHULMAN AMY W
604,482 +inf%
16.00
US$9,671,712 		604,482 +inf% 16.00 US$9,671,712
2019-04-03 2019-04-02 B Purchase
2.0
Currie Mark G

President
270,107 +523.0%
14.81
US$4,000,285 		270,107 +523.0% 14.81 US$4,000,285
Explore more

More insider trading research around Cyclerion Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America